Drug challenges in “intact” and p-chlorophenylalanine (p-CPA)-treated animals can be used to distinguish agents that act as direct serotonin (5-HT) agonists from agents that function as 5-HT releasers.
ObjectivesThe objective of the study was to investigate the effect of p-CPA treatment on the capacity of racemic 3,4-methylenedioxymethamphetamine (MDMA) and its stereoisomers to induce the head twitch response, hyperthermia, and locomotor stimulation in mice.
MethodsPretreatments with either 100 mg/kg p-CPA or equivolume saline were administered for three consecutive days. The following day, mice were either euthanized (to quantify 5-HT tone), tested with various doses of racemic MDMA or one of its enantiomers in the head twitch assay, or challenged with 32 mg/kg racemic MDMA or one of its enantiomers, while temperature and locomotor activity were monitored via radiotelemetry.
Resultsp-CPA reduced cortical 5-HT turnover by >70% without altering dopamine turnover. Racemic MDMA did not induce a significant head twitch response in intact or p-CPA-treated mice. S(+)-MDMA and R(−)-MDMA elicited similar head twitch curves in intact mice; p-CPA treatment attenuated this response when induced by S(+)-MDMA but not when elicited by R(−)-MDMA. Neither the hyperthermic nor locomotor-stimulant effects of racemic MDMA were altered by p-CPA treatment. The hyperthermic effects, but not the locomotor-stimulant effects, of S(+)-MDMA were attenuated in mice treated with p-CPA. R(−)-MDMA did not alter core temperature or induce significant locomotor stimulation in intact or p-CPA-treated mice.
ConclusionsThe effects of S(+)-MDMA on core temperature and head twitch behavior are consistent with a mechanism involving 5-HT release, whereas the effects of R(−)-MDMA on head twitch behavior are consistent with a direct agonist mechanism of action. The actions of the racemate on core temperature and locomotor activity likely involve a combination of 5-HT release and direct agonism at 5-HT receptors.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Similar content being viewed by others Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. ReferencesAcquas E, Marrocu P, Pisanu A, Cadoni C, Zernig G, Saria A, DiChiara G (2001) Intravenous administration of ecstasy (3,4-methylenedioxymethamphetamine) enhances cortical and striatal acetylcholine release in vivo. Eur J Pharmacol 418:207–211
Balsara JJ, Bapat TR, Nandal NV, Gada VP, Chandorkar AG (1986) Head-twitch response induced by ergometrine in mice: behavioural evidence for direct stimulation of central 5-hydroxytryptamine receptors by ergometrine. Psychopharmacology 88(3):275–278
Bankson MG, Cunningham KA (2002) Pharmacological studies of the acute effects of (+)-3,4-methylenedioxymethamphetamine on locomotor activity: role of 5-HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26(1):40–52
Battaglia G, DeSouza E (1989) Pharmacologic profile of amphetamine derivatives at various brain recognition sites: selective effects on serotonin systems. NIDA Res Monogr 94:240–258
Battaglia G, Brooks B, Kulsakdinum C, DeSouza E (1988) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149:159–163
Bengel D, Murphy DL, Andrews AM, Wichems CH, Feltner D, Heils A, Mossner R, Westphal H, Lesch KP (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (“ecstasy”) in serotonin transporter-deficient mice. Mol Pharmacol 53(4):649–655
Bubar MJ, Pack KM, Frankel PS, Cunningham KA (2004) Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA. Psychopharmacology 173(3–4):326–336
Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181–1188
Esteban B, O'Shea E, Camarero J, Sanchez V, Green AR, Colado MI (2001) 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology 154(3):251–260
Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G (2002) 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology 161(4):356–364
Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH (2003) Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine (“ecstasy”) and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 166(3):202–211
Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH (2004a) Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology 173(3–4):270–277
Fantegrossi WE, Kilbourn ME, Woods JH (2004b) Actions of the 5-HT2A antagonist M100907 in serotonin-depleted mice. 2004 Experimental Biology meeting abstracts (accessed at http://select.biosis.org/faseb). FASEB J 18, Abstract #637.2
Fischer H, Zernig G, Schatz D, Humpel C, Saria A (2001) MDMA (ecstasy) enhances basal acetylcholine release in brain slices of the rat striatum. Eur J Neurosci 12:1385–1390
Joseph JA, Appel JB (1977) Behavioral sensitivity to LSD: dependency upon the pattern of central 5HT depletion. Pharmacol Biochem Behav 6:499–504
Mazzola-Pomieto P, Aulakh C, Tolliver T, Murphy D (1997) Functional subsensitivity to 5HT2A and 5HT2C receptors mediating hyperthermia following acute and chronic treatment with 5HT2A/2C receptor agonists. Psychopharmacology 130:144–151
Nair SG, Gudelsky GA (2004) Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Res 1013(2):168–173
Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18(4):305–313
Nichols DE, Lloyd DH, Hoffman AJ, Nichols MB, Yim GKW (1982) Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. J Med Chem 25:530–534
Piazza PV, Rouge-Pont F, Deminiere JM, Kharoubi M, Le Moal M, Simon H (1991) Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res 567(1):169–174
Schmidt CJ, Black CK, Abbate GM, Taylor VL (1990) Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Brain Res 529(1–2):85–90
Setola V, Hufeisen SJ, Grande-Allen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL (2003) 3,4-Methylenedioxymethamphetamine (MDMA, “ecstasy”) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223–1229
Wise RA, Bozarth MA (1987) A psychomotor stimulant theory of addiction. Psychol Rev 94(4):469–492
The authors express their gratitude to the University of Michigan Undergraduate Research Opportunity Program and for the expert technical assistance provided by the University of Michigan Unit for Laboratory Animal Medicine staff.
These studies were supported by USPHS grants DA09161 and DA05923.
Author information Authors and AffiliationsDivision of Neuroscience, Yerkes National Primate Research Center, Emory University, 954 Gatewood Drive, Atlanta, GA, 30322, USA
William E. Fantegrossi
Department of Pharmacology, University of Michigan Medical School, 1301 MSRB III, 1150 West Medical Center Drive, Ann Arbor, MI, 48109-0632, USA
William E. Fantegrossi, Christina L. Kiessel & James H. Woods
Department of Psychiatry, Neuropsychiatric Institute, A8-148, University of California Los Angeles, Los Angeles, CA, 90024, USA
Richard De La Garza II
Correspondence to William E. Fantegrossi.
About this article Cite this articleFantegrossi, W.E., Kiessel, C.L., De La Garza, R. et al. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology 181, 529–536 (2005). https://doi.org/10.1007/s00213-005-0005-8
Received: 27 November 2004
Accepted: 15 March 2005
Published: 28 June 2005
Issue Date: September 2005
DOI: https://doi.org/10.1007/s00213-005-0005-8
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4